Corneal graft surgery combined with subconjunctival bevacizumab (Avastin)

Cornea

Volumn 29, Issue 6, 2010, Pages 691-693

  Symes, Richard J ^a   Poole, Thomas R G ^a  

^a FRIMLEY PARK HOSPITAL   (United Kingdom)

Author keywords

Avastin; Bevacizumab; Cornea; Keratoplasty; VEGF

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; STEROID;

ADULT; ARTICLE; CASE REPORT; CATARACT EXTRACTION; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; EYE BURN; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; KERATOPLASTY; MALE; PHACOEMULSIFICATION; PRIORITY JOURNAL; TRAUMATIC CATARACT;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CATARACT; COMBINED MODALITY THERAPY; CONJUNCTIVA; CORNEA; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; EYE BURNS; GRAFT REJECTION; HUMANS; MALE; PHACOEMULSIFICATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952950938     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181ba0ae2     Document Type: Article

References (24)

1. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
2. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982.
3. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
4. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound and inflammation related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
5. Avery R, Piermici D, Rabena M, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363-372.
6. Hurmeric V, Mumcuoglu T, Edurman C, et al. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea. 2007;27:357-362.
7. Hosseini H, Nejabat M, Mehryar M, et al. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol. 2007;35:745-748.
8. Papathanassiou M, Theodossiadis P, Liarakos V, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-431.
9. Kim T, Kim S, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea. 2008;27:349-352.
10. Harooni H, Reddy V, Root T, et al. Bevacizumab for graft rejection. Ophthalmology. 2007;114:1950.
11. Edurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovas-cularization. Graefes Arch Clin Exp Ophthalmol. 2007;245:1577-1579.
12. Carrasco M. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea. 2008;27:743-745.
13. Doctor P, Bhat P, Foster C. Subconjunctival bevacizumab for corneal neovascularisation. Cornea. 2008;27:992-995.
14. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;33:23-28. (Pubitemid 351156952)
15. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal vascularization. Cornea. 2008;27:142-147.
16. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993.
17. Qian C, Bahar I, Levinger E, et al. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:1090-1092.
18. Gerten G. Bevacizumab (Avastin) and argon laser to treat neovasculariza-tion in corneal transplant surgery. Cornea. 2008;27:1195-1199.
19. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmol. 2008;27:743-745.
20. Uly HS, Chan SP, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27:70-73.
21. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552.
22. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
23. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008; 86:322-328.
24. Mackenzie SE, Tucker WR, Poole TR. Bevacizumab (Avastin) for corneal neovascularization - corneal light shield soaked application. Cornea. 2009;28:246-247.